Navigation Links
Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
Date:9/21/2010

nitial registration statement, Anthera has agreed to file subsequent registration statements until all the shares have been registered, and the registration rights agreement imposes certain customary cash penalties on Anthera for its failure to satisfy specified filing and effectiveness time periods.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (or BAFF, or BLyS), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include statements relating to whether and when the private placement will close, Anthera's anticipated uses of the net proceeds of the transaction and whether and when Anthera's Board of Directors will appoint Dr. Peter Thompson to Anthera's Board of Directors. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cau
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
2. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
3. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
4. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
5. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
6. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
11. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... ORLANDO, Fla. , May 18, 2013 ... and are considered the most sensitive method for ... completely effective in preventing cancer cases 3 . EndoChoice ... its new Fuse™ system significantly improves the accuracy of ... missed by colonoscopists. EndoChoice will be discussing these clinical ...
(Date:5/18/2013)... May 18, 2013 The Open Paradigm ... Occupy Psychiatry , and leading organizations ... announces a social media campaign showcasing video testimonials ... model, which focuses on pathology and illness rather ... the American Psychiatric Association,s (APA) rollout of its ...
(Date:5/18/2013)... 2013 Faruqi & Faruqi, LLP, a ... securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses ... federal securities laws by issuing materially false and/or ... trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, the ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... Dec. 23 BioTrends Research Group, Inc. published ... in the United States," based on ... clinical practice. The report evaluates patient types, ... Hematologists, Oncologists, Nephrologists, Gastroenterologists, OB-GYNs, Rheumatologists, Cardiologists and ...
... , , , PARIS, December ... discovery and development of novel antibiotics,designed to overcome the ... its shareholders have signed a definitive,agreement whereby Novexel shall ... up to $505 million, including contingent payments and the,net ...
Cached Medicine Technology:BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties 2Novexel to be Acquired by AstraZeneca 2Novexel to be Acquired by AstraZeneca 3Novexel to be Acquired by AstraZeneca 4
(Date:5/18/2013)... American Society for Gastrointestinal Endoscopy (ASGE) will honor important ... annual ASGE Crystal Awards on Sunday, May 19, 2013. ... event will begin at 6:30 ... in conjunction with Digestive Disease Week (DDW), the ASGE ... scientific pursuit. The event will recognize the 2013 award ...
(Date:5/18/2013)... FL (May 19, 2013) Each year, the ... their outstanding contributions and achievements in gastroenterology through ... of many distinguished and talented individuals who work ... gastroenterology. Today, we are pleased to announce the ... by their colleagues for their tremendous contributions to ...
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The American ... announce its 2013 research scholars. This year,s honorees ... in gastroenterology, hepatology or related areas, and with ... , "These young researchers are the future ... young scholars who are paving the way for ...
(Date:5/18/2013)... 2013 Also known as bariatric ... weight loss surgery that guarantees patients long-term weight loss. ... wishes to give readers a brief tutorial on this ... school at New York City’s Mount Sinai School of ... undertook a fellowship in Minimally Invasive Bariatric Surgery. He ...
(Date:5/18/2013)... 18, 2013 Online watch retailer Time and ... watch owners at a fraction of its usual cost. ... in the world, buyers are urged to take advantage of ... a Rolex watch from a brick-and-mortar store, buyers now have ... watches priced at unbelievable rates. Although some buyers may have ...
Breaking Medicine News(10 mins):Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3
... grant from the Office of the National Coordinator ... Hospital Boston and Harvard Medical School have developed ... flexible health information technology (IT) environment and promote ... platform and interface are being made publicly available ...
... (BA) is an inflammatory obliterative cholangiopathy with unknown ... technology, emerged as an indispensable research tool for ... the mechanism underlying BA, and allows the simultaneous ... experiment. Some studies have been performed to investigate ...
... , MONDAY, March 7 (HealthDay News) -- Children prefer cereals ... package, regardless of how they taste, researchers say. "This ... are going to be more likely to enjoy their cereal ... said Keri Gans, a spokeswoman for the American Dietetic Association ...
... 8, 2011 As the debate about healthcare in the ... issue of The American Journal of Medicine strive ... dialog. The issue leads off with the editorial, "The ... Dr. Joseph Alpert, Professor of Medicine, Arizona College of Medicine, ...
... , MONDAY, March 7 (HealthDay News) --Taste cells apparently ... formerly thought to exist only in the pancreas and ... to the development of new interventions designed to help ... sweetness of nutritive sugars is one of the most ...
... LA JOLLA, CA, AND JUPITER, FL March 7, ... until March 7, 2011, 3 PM, Eastern time Working ... to find potential medicines and other biologically useful molecules, ... of Technology (MIT) have discovered an extremely potent class ...
Cached Medicine News:Health News:Boston researchers create 'SMArt' platform architecture, launch $5,000 health app competition 2Health News:Cartoon Branding Affects Kids' Cereal Choice, Regardless of Taste 2Health News:Cartoon Branding Affects Kids' Cereal Choice, Regardless of Taste 3Health News:The sorry state of health of US medicine 2Health News:The sorry state of health of US medicine 3Health News:The sorry state of health of US medicine 4Health News:New Sweetness Detectors Found in Human Taste Cells 2Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 2Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 3Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 4
... research model of the Bowman Perfusion Monitor ... continuously in real-time. This precision instrument activates ... which is connected by an umbilical cord ... digital form and send the data to ...
Housed in a small lightweight, flame retardant plastic cases, meters are equipped with a convenient multiposition handle/stand. Measure microcirculation in 1 cubic mm of tissue for real-time assessme...
... featured laser doppler system for continuous ... multiple tissue sites. This latest generation ... Processing (DSP) and laser Doppler flowmetry ... to use, multi-channel monitor, setting new ...
Transcranial vascular DWL doppler....
Medicine Products: